Search results for "Receptor tyrosine kinase"

showing 10 items of 82 documents

Suppression of ischemia-induced fos expression and AP-1 activity by an antisense oligodeoxynucleotide to c-fos mRNA.

1994

The molecular events of brain adaptation to injury that may underlie functional recovery after stroke remain largely undefined. Recent observations of altered gene expression in ischemic brain using animal stroke models have opened new avenues for exploration of the biochemical cascades after stroke [1–11]. These postischemic events include an increase in extracellular excitatory amino acid neurotransmitters such as glutamate. Glutamate receptor–mediated activation of phospholipases and protein kinases results in the alteration of nuclear regulatory processes, including the expression of immediate early genes such as c-fos, junB, and c-jun [5, 12]. The Fos, Jun, and JunB proteins have been …

Messenger RNAbiologyBase SequenceJUNBEffectorOligonucleotideMolecular Sequence DataGene ExpressionOligonucleotides Antisensec-FosMolecular biologyReceptor tyrosine kinaseArticleRatsTranscription Factor AP-1NeurologyTranscription (biology)Ischemic Attack TransientGene expressionbiology.proteinAnimalsNeurology (clinical)RNA MessengerProto-Oncogene Proteins c-fosAnnals of neurology
researchProduct

Investigation of new 2-aryl substituted Benzothiopyrano[4,3-d[pyrimidines as kinase inhibitors targeting vascular endothelial growth factor receptor 2

2015

Vascular Endothelial Growth Factor (VEGF) pathway has emerged as one of the most important positive modulators of Angiogenesis, a central process implicated in tumour growth and metastatic dissemination. This led to the design and development of anti-VEGF monoclonal antibodies and small-molecule ATP-competitive VEGFR-inhibitors. In this study, we describe the synthesis and the biological evaluation of novel 2-aryl substituted benzothiopyrano-fused pyrimidines 1a-i, 2a-i and 3a-i. The ability of the compounds to target the VEGF pathway was determined in vitro exploiting the compounds' antiproliferative efficacy against HUVEC cells. The VEGFR-2 inhibition was confirmed by enzymatic assays on …

Models MolecularAngiogenesisReceptor tyrosine kinaseCellAntineoplastic AgentsReceptor tyrosine kinaseBenzothiopyranopirimidines; Kinase inhibitors; Receptor tyrosine kinases; Tumor angiogenesis; VEGFR;Tumor angiogenesisStructure-Activity Relationshipchemistry.chemical_compoundVEGFRBenzothiopyranopirimidineCell Line TumorReceptor tyrosine kinasesDrug DiscoveryHuman Umbilical Vein Endothelial CellsmedicineHumansProtein Kinase InhibitorsCell ProliferationPyransTumor angiogenesiPharmacologyKinase inhibitorDose-Response Relationship DrugMolecular StructurebiologyKinaseCell growthOrganic ChemistryKinase insert domain receptorGeneral MedicineVascular Endothelial Growth Factor Receptor-2Molecular biologyVascular endothelial growth factorPyrimidinesmedicine.anatomical_structureBenzothiopyranopirimidineschemistryBenzothiopyranopirimidines; Kinase inhibitors; Receptor tyrosine kinases; Tumor angiogenesis; VEGFRKinase inhibitorsCancer researchbiology.proteinDrug Screening Assays AntitumorEx vivo
researchProduct

Multiple Ig-like featuring genes divergent within and among individuals of the marine sponge Geodia cydonium.

1998

Abstract The receptor tyrosine kinase of the marine sponge Geodia cydonium features two extracellular Ig-like domains in which we recently documented RT-PCR polymorphism among individuals. Genomic-PCR analysis presented here revealed 14 unique sequences from four sponges, differing predominantly in the sequence of an intron which splits the Ig-like domains. Nevertheless, analysis of putative coding regions in 19 distinct clones (156–159 aa) from seven sponges revealed 69 positions of nucleotide substitutions, 67.6% of them non-synonymous, translating into 43 positions of divergent residues. Excluding aa deletions, these 19 sequences share pairwise aa identities of 89–99%. In three sponges, …

Molecular Sequence DataImmunoglobulinsGenomePolymerase Chain ReactionReceptor tyrosine kinaselaw.inventionlawMHC class IGeneticsCoding regionAnimalsHumansAmino Acid SequenceGenePolymerase chain reactionGeneticsPolymorphism GeneticbiologyBase SequenceSequence Homology Amino AcidIntronReceptor Protein-Tyrosine KinasesGeneral MedicineDNAbiology.organism_classificationIntronsPoriferaSpongeMultigene Familybiology.proteinSequence AlignmentGene
researchProduct

Identification of a novel type of ITD mutations located in nonjuxtamembrane domains of the FLT3 tyrosine kinase receptor

2009

Abstract In acute myeloid leukemia (AML), internal tandem duplications (ITDs) of the juxtamembrane (JM) of FLT3 have been shown to play a crucial role in driving proliferation and survival of the leukemic clone. Here, we report the identification of FLT3_ITD mutations located in non-JM domains of the FLT3-receptor. This novel type of FLT3_ITD mutation was found in 216 of 753 (28.7%) of unselected FLT3_ITD-positive AML cases. An FLT3 receptor harbouring a prototypic non-JM ITD (FLT3_ITD627E) mediated constitutive phosphorylation of FLT3 and of STAT5, suggesting that non-JM ITDs confer constitutive activation of the receptor. FLT3_ITD627E induced transformation of hematopoietic 32D cells and …

MutationImmunologyClone (cell biology)MedizinMyeloid leukemiaCell BiologyHematologyBiologymedicine.disease_causeBiochemistryMolecular biologyReceptor tyrosine kinasehemic and lymphatic diseasesTrk receptormedicinebiology.proteinPhosphorylationReceptorSTAT5
researchProduct

IRS2 signalling is required for the development of a subset of sensory spinal neurons

2012

Insulin and insulin-like growth factor-I play important roles in the development and maintenance of neurons and glial cells of the nervous system. Both factors activate tyrosine kinase receptors, which signal through adapter proteins of the insulin receptor substrate (IRS) family. Although insulin and insulin-like growth factor-I receptors are expressed in dorsal root ganglia (DRG), the function of IRS-mediated signalling in these structures has not been studied. Here we address the role of IRS2-mediated signalling in murine DRG. Studies in cultured DRG neurons from different embryonic stages indicated that a subset of nerve growth factor-responsive neurons is also dependent on insulin for …

Nervous systemmedicine.medical_specialtybiologyGeneral NeuroscienceInsulinmedicine.medical_treatmentGrowth factorReceptor tyrosine kinaseIRS2Insulin-like growth factorEndocrinologymedicine.anatomical_structurenervous systemInternal medicineInsulin receptor substratebiology.proteinmedicineReceptorEuropean Journal of Neuroscience
researchProduct

FOLFIRI plus sunitinib versus FOLFIRI alone in advanced chemorefractory esophagogastric cancer patients: A randomized placebo-controlled multicentric…

2013

4086 Background: Sunitinib is an receptor tyrosine kinase (RTK) inhibitor of VEGFR1-3, PDGFR-α-β, and other RTK. After we established Sunitinib (Sun) alone associated with limited response rate (RR) and good tolerability in refractory advanced esophagogastric cancer patients (Moehler et al. EUR J Cancer. 2011, 47: 1511), this double-blinded placebo-controlled phase II evaluated safety and efficacy of SUN as add-on in second-line or third-line FOLFIRI (ClinicalTrials.gov NCT01020630). Methods: Patients with failure of any prior docetaxel and/or platinum-based chemotherapy were randomized to receive 6-week cycles including FOLFIRI two weekly and SUN (25 mg) versus (vs) placebo (PLA) daily fo…

OncologyCancer Researchmedicine.medical_specialtybiologySunitinibbusiness.industryPharmacologyPlaceboReceptor tyrosine kinaseOncologyEsophagogastric cancerInternal medicinemedicinebiology.proteinFOLFIRIbusinessmedicine.drug
researchProduct

Coexpression of receptor-tyrosine-kinases in gastric adenocarcinoma-a rationale for a molecular targeting strategy?

2007

AIM: To define the (co-)expression pattern of target receptor-tyrosine-kinases (RTK) in human gastric adenocarcinoma. METHODS: The (co-)expression pattern of VEGFR1-3, PDGFRα/β and EGFR1 was analyzed by RT-PCR in 51 human gastric adenocarcinomas. In addition, IHC staining was applied for confirmation of expression and analysis of RTK localisation. RESULTS: The majority of samples revealed a VEGFR1 (98%), VEGFR2 (80%), VEGFR3 (67%), PDGFRα (82%) and PDGFRβ (82%) expression, whereas only 62% exhibited an EGFR1 expression. 78% of cancers expressed at least four out of six RTKs. While VEGFR1-3 and PDGFRα revealed a predominantly cytoplasmatic staining in tumor cells, accompanied by an additiona…

Pathologymedicine.medical_specialtyStromal cellAntineoplastic AgentsAdenocarcinomaReceptor tyrosine kinaseStomach NeoplasmsmedicineGastric mucosaHumansProtein Kinase InhibitorsbiologyReverse Transcriptase Polymerase Chain ReactionfungiGastroenterologyReceptor Protein-Tyrosine KinasesCancerGeneral Medicinemedicine.diseaseImmunohistochemistrydigestive system diseasesStainingmedicine.anatomical_structureGastric MucosaDrug Designbiology.proteinCancer researchAdenocarcinomaImmunohistochemistryDrug Therapy CombinationRapid CommunicationPlatelet-derived growth factor receptorWorld Journal of Gastroenterology
researchProduct

Does expression of receptor tyrosine kinases in gastric adenocarcinoma correlate with clinicopathological parameters?

2009

Introduction: The prognosis for patients with gastric cancer depends on the stage of the disease. Radical surgery and lymph node dissection represent the only curative intent and are the standard therapeutic option for patients with limited disease. As new multi-targeted receptor tyrosine kinase inhibitors (RTK) are ermerging in the therapy of diverse malignomas, our aim was to analyze the relevance of the targeted receptor tyrosine kinases on local growth, lymphatic dissemination and overall survival in gastric adenocarcinoma. Methods: The (co-)expression pattern of VEGFR1, VEGFR2, VEGFR3, PDGFRα, PDGFRβ and EGFR1 was analyzed by RT-PCR in 56 consecutive samples of human gastric adenocarci…

Pathologymedicine.medical_specialtybiologybusiness.industryStomachCancermedicine.diseasedigestive system diseasesReceptor tyrosine kinasemedicine.anatomical_structureTumor progressionmedicinebiology.proteinCancer researchAdenocarcinomaStomach cancerbusinessLymph nodeSurvival rate
researchProduct

Review: How was metazoan threshold crossed? The hypothetical Urmetazoa.

2001

The origin of Metazoa remained — until recently — the most enigmatic of all phylogenetic problems. Sponges [Porifera] as ‘living fossils’, positioned at the base of multicellular animals, have been used to answer basic questions in metazoan evolution by molecular biological techniques. During the last few years, cDNAs/genes coding for informative proteins have been isolated and characterized from sponges, especially from the marine demosponges Suberites domuncula and Geodia cydonium. The analyses of their deduced amino acid sequences allowed a molecular biological resolution of the monophyly of Metazoa. Molecules of the extracellular matrix/basal lamina, with the integrin receptor, fibronec…

PhysiologyMolecular Sequence DataBiochemistryReceptor tyrosine kinaseMyotrophinMorphogenesisAnimalsAmino Acid SequenceeducationMolecular BiologyGeneGalectineducation.field_of_studybiologySequence Homology Amino AcidCell adhesion moleculebiology.organism_classificationBiological EvolutionInvertebratesCell biologyPoriferaSuberites domunculaIntracellular signal transductionGerm Cellsbiology.proteinSignal transductionCell Adhesion MoleculesSignal TransductionComparative biochemistry and physiology. Part A, Molecularintegrative physiology
researchProduct

Conformational clamping by a membrane ligand activates the EphA2 receptor

2021

AbstractThe EphA2 receptor is a promising drug target for cancer treatment, since EphA2 activation can inhibit metastasis and tumor progression. It has been recently described that the TYPE7 peptide activates EphA2 using a novel mechanism that involves binding to the single transmembrane domain of the receptor. TYPE7 is a conditional transmembrane (TM) ligand, which only inserts into membranes at neutral pH in the presence of the TM region of EphA2. However, how membrane interactions can activate EphA2 is not known. We systematically altered the sequence of TYPE7 to identify the binding motif used to activate EphA2. With the resulting six peptides, we performed biophysical and cell migratio…

Protein ConformationSequence HomologyTm ligandsPeptideMolecular Dynamics SimulationLigandsReceptor tyrosine kinaseArticleBimolecular fluorescence complementationProtein DomainsStructural BiologyCell MovementCell surface receptorTumor Cells CulturedHumansAmino Acid SequenceReceptorMolecular BiologyMelanomachemistry.chemical_classificationBinding SitesMembranesbiologyChemistryReceptor EphA2Membrane ProteinsLigand (biochemistry)Peptide FragmentsTransmembrane proteinTransmembrane domainMembranebiology.proteinBiophysicsProtein MultimerizationProtein Binding
researchProduct